Related Experiment Video
Updated: May 20, 2026
06:57
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
HPV detection methods in head and neck cancer.
Aldo Venuti1, Francesca Paolini
1Laboratory of Virology, Regina Elena National Cancer Institute, Rome, Italy. venuti@ifo.it
Head and Neck Pathology
|July 12, 2012
Summary
Detecting human papillomavirus (HPV) in head and neck cancers is crucial for prognosis. This review explores various HPV detection methods for head and neck squamous cell carcinoma (HNSCC) to guide clinical application.
Area of Science:
- Oncology
- Virology
- Molecular Diagnostics
Background:
- Human papillomavirus (HPV) infection is an increasingly important prognostic and predictive factor in head and neck squamous cell carcinoma (HNSCC).
- Unlike cervical cancer, HPV status in HNSCC provides significant prognostic information for established tumors.
- The clinical relevance of HPV in HNSCC necessitates reliable detection methods to differentiate HPV-associated from non-HPV-associated tumors.
Purpose of the Study:
- To review and explain various HPV detection techniques applicable to HNSCC.
- To highlight the clinical utility of different HPV diagnostic methodologies.
- To discuss emerging techniques, including serum/plasma-based assays and DNA/RNA microarrays, for HPV detection and molecular profiling in HNSCC.
Main Methods:
- Review of existing literature on HPV detection assays for HNSCC.
- Discussion of established methods: HPV polymerase chain reaction (PCR) testing, HPV in situ hybridization (ISH), and p16 immunohistochemistry (IHC).
- Exploration of novel approaches: serum/plasma HPV detection and DNA/RNA microarray platforms for molecular profiling.
Main Results:
- Multiple methodologies exist for HPV detection in HNSCC, including PCR, ISH, and p16 IHC, but no single optimal method is universally agreed upon.
- Serum and plasma-based HPV detection methods are under development, offering potential future clinical applications despite current specificity limitations.
- DNA/RNA microarray platforms can identify molecular changes in HPV-positive and HPV-negative HNSCC, aiding in transcriptome-based diagnosis and risk stratification.
Conclusions:
- Accurate HPV detection is vital for managing HNSCC, impacting prognosis and treatment decisions.
- A range of techniques are available, each with specific advantages and limitations, requiring careful consideration for clinical implementation.
- Future research into novel detection methods and molecular profiling holds promise for personalized risk assessment and improved patient outcomes in HNSCC.
